Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 avutometinib + defactinib vs investigator's choice in recurrent low-grade serous ovarian cancer
jRCT2051250070Phase 3Recruiting
- Sponsor
- Verastem Oncology
- Start
- Jul 2025
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, open-label trial of avutometinib and defactinib in low-grade serous ovarian carcinoma (LGSOC), fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (2 arms), sponsored by Verastem Oncology. Primary endpoint: Progression-free survival per blinded independent central review. Started Jul 2025; status: recruiting.
02
Drugs
avutometinibdefactinib
03
Conditions
low-grade serous ovarian carcinoma (LGSOC)fallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on jRCT2051250070.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051250070.